Recent advances from the Autism Biomarkers Consortium highlight stable electroencephalography and eye-tracking measures capable of distinguishing autistic children, yet still fall short of providing precise individual diagnostics amid autism’s heterogeneity.
A pair of measures from a long-running autism research consortium has emerged as the most dependable so far, according to a paper highlighted by The Transmitter. One comes from electroencephalography, which records electrical activity in the brain, and the other from an eye-tracking task. Both appear stable over time and able to distinguish autistic from non-autistic children, but researchers say they still capture only part of the picture.
The work comes from the Autism Biomarkers Consortium for Clinical Trials, a multi-site effort designed to test whether candidate markers can support autism studies and, eventually, treatment trials. Earlier reports from the consortium described a tightly standardised approach across sites, with careful data quality checks and a focus on children aged six to 11 with and without autism. That design was intended to reduce noise and make it easier to judge whether any measure was robust enough for wider use.
In the EEG arm of the project, researchers found that certain brain-based signals could reliably separate groups, but the results were not simple enough to serve as a stand-alone clinical test. The eye-tracking work reached a similar conclusion. Measures related to looking at faces and biological motion showed promise and were reasonably stable, yet the responses varied substantially from child to child. Studies published in 2021 and 2022 also stressed that the tasks may help in research settings while still needing further validation before they can be used more broadly.
That nuance matters because autism is highly heterogeneous. The markers may be useful for stratifying groups in trials or tracking whether an intervention is affecting brain or attention systems, but the associations with individual clinical traits remain modest. In other words, the biomarkers appear good at identifying broad patterns, while offering only limited insight into how autism presents in any one child. The latest findings, as The Transmitter notes, underline both the progress and the limits of biomarker research in this area.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
